Comparative validation of UV-spectrophotometry and RP-HPLC methods for cefixime and moxifloxacin analysis.

This study focuses on comparative validation of uv-spectrophotometry and rp-hplc methods for cefixime and moxifloxacin analysis.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the pharmaceutical field. This study presents the development and validation of UV-spectrophotometry and RP-HPLC methods for the simultaneous quantification of Cefixime Trihydrate (CEFI) and Moxifloxacin Hydrochloride (MOXI) in pharmaceutical formulations.... Research Background and Significance The pharmaceutical industry demands highly accurate and reliable analytical methods to ensure the quality, safety, and efficacy of drug products. Cefixime Trihydrate (CEFI) and Moxifloxacin Hydrochloride (MOXI) are widely used antibiotics, often formulated together to treat bacterial infections effectively. Precise quantification of these active pharmaceutical ingredients (APIs) in formulations is critical for quality control and regulatory compliance. Traditional UV-spectrophotometry offers a straightforward and cost-effective approach but can lack specificity in multi-component systems. Reversed-phase high-performance liquid chromatography (RP-HPLC) provides enhanced selectivity and sensitivity, making it a preferred choice for simultaneous analysis of complex formulations. This study by Chaudhari et al. undertakes a comparative validation of UV-spectrophotometric and RP-HPLC methods, emphasizing the chromatographic technique's robustness for dual quantification of CEFI and MOXI in pharmaceutical preparations. Experimental Design and Methodology The study developed and validated two analytical methods: UV-spectrophotometry and RP-HPLC, focusing on the simultaneous determination of CEFI and MOXI. The RP-HPLC method employed a reversed-pha